Abstract:Cardiac remodelling is a common pathophysiological process in the development of various cardiovascular diseases, but there is still a lack of effective interventions. Tumour necrosis receptor-associated factor 7 (TRAF7) belongs to the tumour necrosis factor receptor-associated factor family and plays an important role in biological processes. Previous studies have shown that TRAF7 mutations lead to congenital defects and malformations of the heart. However, the molecular mechanisms of TRAF7 in the underlying pathogenesis of pathological cardiac hypertrophy remain unknown. We aim to study the molecular mechanisms and effects of TRAF7 in cardiac remodelling and whether it has the potential to become a therapeutic target for cardiac remodelling. The pressure overload–induced cardiac hypertrophy model in mice was established via transverse aortic constriction (TAC) surgery, and cardiomyocytes were treated with phenylephrine (PE) to induce hypertrophic phenotype. Levels of cardiac dysfunction and remodelling were measured with echocardiography and tissue or cell staining. RNA sequencing, western blot, qRT–PCR, co-immunoprecipitation, and in vivo ubiquitination assays were used to explore the molecular mechanisms. The results showed that the expression of TRAF7 increased gradually during the development of hypertrophy. Accordingly, TRAF7 significantly exacerbated the PE-induced enlargement of primary neonatal Sprague-Dawley rat cardiomyocytes, whereas TRAF7 knockdown alleviated the hypertrophic phenotype in primary cardiomyocytes. Cardiac-specific overexpression of TRAF7 accelerated hypertrophic phenotype in mice and cardiac-specific Traf7 conditional knockout mice improved hypertrophic phenotype induced by TAC. Mechanistically, TRAF7 directly interacted with apoptosis signal-regulating kinase-1 (ASK1) and promoted ASK1 phosphorylation by mediating the K63-linked ubiquitination of ASK1 in response to PE stimulation, which then promoted ASK1 activation and downstream signalling during cardiac hypertrophy. Notably, the pro-hypertrophic effect of TRAF7 was largely blocked by GS4997 in vitro and cardiac-specific Ask1 conditional knockout in vivo . In summary, we identified TRAF7 as an essential regulator during cardiac hypertrophy, and modulation of the regulatory axis between TRAF7 and ASK1 could be a novel therapeutic strategy to prevent this pathological process. A schematic diagram of the molecular mechanisms underlying tumour necrosis receptor-associated factor 7 (TRAF7)-regulated cardiac hypertrophy. Under hypertrophic stimulation, reactive oxygen specices (ROS)-triggered TRAF7 expressing binds to the apoptosis signal-regulating kinase-1 (ASK1) through its WD40 repeats domain and applies the ring domain to promote the ubiquitination of lys1064 in ASK1 via the K63 ubiquitin chain, thereby promoting ASK1 phosphorylation and then activating JNK/p38 axis in cardiomyocytes.

Src Tyrosine Kinase Promotes Cardiac Remodeling Induced by Chronic Sympathetic Activation.

Ang II Enhances Atrial Fibroblast Autophagy and Promotes Atrial Remodeling Through the AT1-ERK-mTOR Signaling Pathway

Crosstalk between Src and β-arrestin2 orchestrates cardiac hypertrophic responses under mechanical stresses

Vascular Endothelial S1pr1 Ameliorates Adverse Cardiac Remodelling Via Stimulating Reparative Macrophage Proliferation after Myocardial Infarction.

C-Reactive Protein Promotes Cardiac Inflammation and Fibrosis in Angiotensin Ii-Induced Hypertensive Cardiovascular Diseases

Exacerbating Pressure Overload–Induced Cardiac Hypertrophy

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling

Endothelial S1pr1 Regulates Pressure Overload‐induced Cardiac Remodelling Through AKT‐eNOS Pathway

Krüppel-Like Factor 15 Modulates CXCL1/CXCR2 Signaling-Mediated Inflammatory Response Contributing to Angiotensin II-Induced Cardiac Remodeling

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Src is Required for Mechanical Stretch-Induced Cardiomyocyte Hypertrophy Through Angiotensin II Type 1 Receptor-Dependent Β-Arrestin2 Pathways.

Beta-adrenoceptor Signaling Pathways Mediate Cardiac Pathological Remodeling.

Inhibition of Src improves cardiac fibrosis in AngII-induced hypertrophy by regulating the expression of galectin-3

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Transactivated EGFR Mediates Α₁-Ar-induced STAT3 Activation and Cardiac Hypertrophy.

Angiotensin II Causes Biphasic STAT3 Activation Through TLR4 to Initiate Cardiac Remodeling

Downregulation of Β-Adrenoceptors in Isoproterenol-Induced Cardiac Remodeling Through HuR

Distinct Actions of Intermittent and Sustained Β-Adrenoceptor Stimulation on Cardiac Remodeling

Cardiac tumour necrosis factor receptor-associated factor 7 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and aggravates cardiac hypertrophy

Src Tyrosine Kinase Regulates Angiotensin II-induced Protein Kinase Cζ Activation and Proliferation in Vascular Smooth Muscle Cells